SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Akoya Biosciences, Inc. (Nasdaq – AKYA)

BALA CYNWYD – April 23, 2025/Globe Newswire/ – Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Akoya Biosciences, Inc. (“Akoya Biosciences” or the “Company”) (Nasdaq – AKYA) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Quanterix Corporation (Nasdaq – QTRX). Under the terms of the all-stock transaction, Akoya Biosciences shareholders will receive 0.318 shares of Quanterix common stock for each share of Akoya common stock owned. Following the close of the transaction, Quanterix shareholders will own approximately 70% of the combined company and Akoya shareholders will own approximately 30%, on a fully diluted basis.

The investigation concerns whether the Akoya Biosciences Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the Company’s shareholders are receiving fair value for their shares.

If you own shares of Akoya Biosciences stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman by email at clients@brodsky-smith.com, or call toll free 855-576-4847.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.